Sensitivity and specificity of community fecal immunotesting screening for colorectal carcinoma in a high-risk canadian population

Archives of Pathology and Laboratory Medicine

Volumn 139, Issue 11, 2015, Pages 1441-1445

  Crouse, Amber L ^a,b   De Koning, Lawrence ^a,b   Sadrzadeh, S M Hossein ^a,b   Naugler, Christopher ^a,b,c  

^a CALGARY LABORATORY SERVICES   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; CANADA; CHEMISTRY; COLONOSCOPY; COLORECTAL NEOPLASMS; COMMUNITY CARE; EARLY CANCER DIAGNOSIS; FECES; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MASS SCREENING; MIDDLE AGED; PROCEDURES; RISK FACTOR; SENSITIVITY AND SPECIFICITY; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CANADA; COLONOSCOPY; COLORECTAL NEOPLASMS; COMMUNITY HEALTH SERVICES; EARLY DETECTION OF CANCER; FECES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MASS SCREENING; MIDDLE AGED; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 84945973953     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2014-0454-OA     Document Type: Conference Paper

References (24)

1. Richter S. Fecal DNA screening in colorectal cancer. Can J Gastroenterol. 2008; 22 (7): 631-633.
2. Labianca R, Merelli B. Screening and diagnosis for colorectal cancer: Present and future. Tumori. 2010; 96 (6): 889-901.
3. Levin TR, Jamieson L, Burley DA, Reyes J, Oehrli M, Caldwell C. Organized colorectal cancer screening in integrated health care systems. Epidemiol Rev. 2011; 33 (1): 101-110.
4. Allard J, Cosby R, Del Giudice ME, Irvine EJ, Morgan D, Tinmouth J. Gastroscopy following a positive fecal occult blood test and negative colonoscopy: Systematic review and guideline. Can J Gastroenterol. 2010; 24 (2): 113-120.
5. Moiel D, Thompson J. Early detection of colon cancer-The Kaiser Permanente Northwest 30-year history: How do we measure success?: Is it the test, the number of tests, the stage, or the percentage of screen-detected patients? Perm J. 2011; 15 (4): 30-38.
6. Guittet L, Bouvier V, Mariotte N, et al. Comparison of a guaiac and an immunochemical faecal occult blood test for the detection of colonic lesions according to lesion type and location. Br J Cancer. 2009; 100 (8): 1230-1235.
7. Launoy GD, Bertrand HJ, Berchi C, et al. Evaluation of an immunochemical fecal occult blood test with automated reading in screening for colorectal cancer in a general average-risk population. Int J Cancer. 2005; 115 (3): 493-496.
8. Oort FA, Terhaar Sive Droste JS, Van Der Hulst RW, et al. Colonoscopycontrolled intra-individual comparisons to screen relevant neoplasia: Faecal immunochemical test vs. guaiac-based faecal occult blood test. Aliment Pharmacol Ther. 2010; 31 (3): 432-439.
9. Daly JM, Bay CP, Levy BT. Evaluation of fecal immunochemical tests for colorectal cancer screening. J Prim Care Community Health. 2013; 4 (4): 245-250.
10. Day LW, Bhuket T, Allison J. FIT testing: An overview. Curr Gastroenterol Rep. 2013; 15 (11): 357.
11. Ciatto S, Martinelli F, Castiglione G, et al. Association of FOBT-Assessed faecal Hb content with colonic lesions detected in the Florence screening programme. Br J Cancer. 2007; 96 (2): 218-221.
12. Rabeneck L, Rumble RB, Thompson F, et al. Fecal immunochemical tests compared with guaiac fecal occult blood tests for population-based colorectal cancer screening. Can J Gastroenterol. 2012; 26 (3): 131-147.
13. Fan J, Upadhye S, Worster A. Understanding receiver operating characteristic (ROC) curves. CJEM. 2006; 8 (1): 19-20.
14. Kovarova JT, Zavoral M, Zima T, et al. Improvements in colorectal cancer screening programmes-quantitative immunochemical faecal occult blood testing-how to set the cut-off for a particular population. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2012; 156 (2): 143-150.
15. van Rossum LG, van Rijn AF, Laheij RJ, et al. Cutoff value determines the performance of a semi-quantitative immunochemical faecal occult blood test in a colorectal cancer screening programme. Br J Cancer. 2009; 101 (8): 1274-1281.
16. Brenner H, Tao S. Superior diagnostic performance of faecal immunochemical tests for haemoglobin in a head-To-head comparison with guaiac based faecal occult blood test among 2235 participants of screening colonoscopy. Eur J Cancer. 2013; 49 (14): 3049-3054.
17. Sharp L, Tilson L, Whyte S, et al. Cost-effectiveness of population-based screening for colorectal cancer: A comparison of guaiac-based faecal occult blood testing, faecal immunochemical testing and flexible sigmoidoscopy. Br J Cancer. 2012; 106 (5): 805-816.
18. Kopcke F, Lubgan D, Fietkau R, et al. Evaluating predictive modeling algorithms to assess patient eligibility for clinical trials from routine data. BMC Med Inform Decis Mak. 2013; 13: 134.
19. Zubero MB, Arana-Arri E, Pijoan JI, et al. Population-based colorectal cancer screening: Comparison of two fecal occult blood test. Front Pharmacol. 2014; 4: 175.
20. Randell E, Kennell M, Taher A, et al. Evaluation of Hemo Techt NS-Plus system for use in a province-wide colorectal cancer screening program. Clin Biochem. 2013; 46 (4-5): 365-368.
21. Levi Z, Rozen P, Hazazi R, et al. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med. 2007; 146 (4): 244-255.
22. Tao S, Seiler CM, Ronellenfitsch U, Brenner H. Comparative evaluation of nine faecal immunochemical tests for the detection of colorectal cancer. Acta Oncol. 2013; 52 (8): 1667-1675.
23. Haug U, Kuntz KM, Knudsen AB, Hundt S, Brenner H. Sensitivity of immunochemical faecal occult blood testing for detecting left-vs right-sided colorectal neoplasia. Br J Cancer. 2011; 104 (11): 1779-1785.
24. Oono Y, Iriguchi Y, Doi Y, et al. A retrospective study of immunochemical fecal occult blood testing for colorectal cancer detection. Clin Chim Acta. 2010; 411 (11-12): 802-805.